<DOC>
	<DOC>NCT02332499</DOC>
	<brief_summary>The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.</brief_summary>
	<brief_title>Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)</brief_title>
	<detailed_description>Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.To compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1. Signed and dated informed consent； 2. Histological or cytological documentation of adenocarcinoma of the colon or rectum； 3. Subjects with metastatic colorectal cancer (Stage IV),With measurable disease (using RECIST1.1)； 4. Progression during or within 3 months following the last administration of approved standard therapies which must include Fluorouracil or its derivatives, Oxaliplatin, Irinotecan； 5. ECOG PS:01,Life expectancy of more than 3 months； 6. main organs function is normal； 7. main organs function is normal； 1. Prior treatment with Anlotinib； 2. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study drug； 3. Known brain metastases； 4. patients with severe and failed to controlled diseases； 5. patients occurred venous thromboembolic events within 6 months；</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Anlotinib</keyword>
	<keyword>Metastatic Colorectal Cancer （mCRC）</keyword>
	<keyword>ALTER0703</keyword>
</DOC>